skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Molecular predictors of therapeutic response to specific anti-cancer agents

Patent ·
OSTI ID:1333733

Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.

Research Organization:
Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
Sponsoring Organization:
USDOE
DOE Contract Number:
AC02-05CH11231
Assignee:
The Regents of the University of California (Oakland, CA)
Patent Number(s):
9,506,926
Application Number:
13/401,780
OSTI ID:
1333733
Resource Relation:
Patent File Date: 2012 Feb 21
Country of Publication:
United States
Language:
English

References (1)


Similar Records

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
Journal Article · Thu Aug 09 00:00:00 EDT 2012 · Breast Cancer Research and Treatment · OSTI ID:1333733

Modeling precision treatment of breast cancer
Journal Article · Tue Jan 01 00:00:00 EST 2013 · GenomeBiology.com · OSTI ID:1333733

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer
Journal Article · Fri Jul 01 00:00:00 EDT 2016 · Breast Cancer Research · OSTI ID:1333733